CA-INFOGAIN
4.1.2022 06:39:11 CET | Business Wire | Press release
Infogain, a Silicon Valley-based global leader in human-centered digital platform engineering services, has appointed Dayapatra Nevatia as President and Chief Operating Officer, responsible for global operations. Reporting to CEO Ayan Mukerji, he will support and execute Infogain’s strategy of combining cloud, experience, and AI to build innovative human-centered digital solutions for our customers.
Nevatia is a well-respected IT industry veteran with close to three decades of experience in client value creation and delivery, incubating new business verticals, managing large P&Ls, and leading culturally diverse global organizations with more than 100,000 global team members. In his most recent role as Mindtree’s Executive Director and Chief Operating Officer, he was responsible for designing, planning, and implementing business strategies and operating plans that align with the company’s vision and long-term goals.
Prior to Mindtree, Nevatia served in senior leadership roles at Accenture for many years. As Managing Director and Director of Delivery for Advanced Technology Centres in India for Accenture, he was part of their Indian executive leadership team, delivering programs in system integration, application outsourcing, infrastructure, digital, and security services across different industry groups.
Infogain CEO Ayan Mukerji said, “Dayapatra brings deep knowledge of managing growth and scale with a solid understanding of technology. Infogain will benefit from this expertise. His addition to our executive leadership team will also add a new perspective and enhance our ability to solve complex business challenges facing our customers today.”
Mukerji continued, “I’d also like to thank Eddie Chandhok for his 18 years of outstanding performance nurturing our organization’s growth. Eddie will stay on with the company and continue to drive Infogain’s M&A function, which is increasingly becoming more strategic as we continue to bring on new talent and integrate new global delivery locations.”
Dayapatra added, “I am excited to be joining a rapidly growing digital engineering company like Infogain, with futuristic leaders who are all-in, building platforms that drive our customers' business.”
Shashank Singh, Partner at Apax, which advises funds that are majority owners of Infogain, said, “Dayapatra’s impressive background and experience working with CEOs, CDOs, and CTOs of Fortune 100 companies make him a great fit for taking Infogain’s delivery and operations to the next level.”
Rohan Haldea, Partner at Apax, added, “This is another exciting step in Infogain’s growth journey and will drive performance excellence in the global team.”
Dayapatra has a bachelor’s degree in Electronics Engineering from IET, Lucknow, and a master’s degree in General Management from IISc, Bangalore.
About Infogain
Infogain is a human-centered digital platform engineering company based out of Silicon Valley. We engineer business outcomes for Fortune 500 companies and digital natives in the technology, healthcare, insurance, travel, telecom, and retail/CPG industries. We accelerate experience-led transformation in the delivery of digital platforms using technologies such as cloud, microservices, automation, IoT, and artificial intelligence. Infogain is a multi-cloud expert across hyperscale cloud providers – Microsoft Azure, Google Cloud Platform, and Amazon Web Services.
Infogain, an Apax Funds portfolio company, has offices in California, Washington, Texas, the UK, the UAE, and Singapore, with delivery centers in Seattle, Houston, Austin, Kraków, Noida, Bengaluru, Pune, Gurgaon, and Mumbai. To learn more, visit www.infogain.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005521/en/
Social Media:
https://www.facebook.com/pages/Enterprise-IT-CompanyInfogain/245846616349?ref=ts
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom